Last reviewed · How we verify
Treatment of carcinoma in situ (CIS) of the urinary bladder
Approved treatments
- Tice Bcg · Pfizer
Clinical guidelines
- FDA label — 1L
TICE BCG is indicated for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Treatment of carcinoma in situ (CIS) of the urinary bladder patent landscape — cliff calendar, originator estates, attackable patents
- Treatment of carcinoma in situ (CIS) of the urinary bladder treatment landscape brief
- Treatment of carcinoma in situ (CIS) of the urinary bladder treatment updates RSS
Frequently asked questions about Treatment of carcinoma in situ (CIS) of the urinary bladder
What drugs treat Treatment of carcinoma in situ (CIS) of the urinary bladder?
Tracked treatments include Tice Bcg.
What is the treatment for Treatment of carcinoma in situ (CIS) of the urinary bladder?
Standard treatment for Treatment of carcinoma in situ (CIS) of the urinary bladder includes Tice Bcg. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Treatment of carcinoma in situ (CIS) of the urinary bladder?
FDA label publishes guidelines for Treatment of carcinoma in situ (CIS) of the urinary bladder. 1 guideline references tracked.
Related
- Treatment landscape: Treatment of carcinoma in situ (CIS) of the urinary bladder patent cliff · Treatment of carcinoma in situ (CIS) of the urinary bladder CI report
- Treatment: Tice Bcg · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing